NUSAP1 enhances ATR stability by promoting its sumoylation and inhibiting its ubiquitin-dependent degradation, thereby promoting resistance to temozolomide and doxorubicin in glioma [21]. Here, NUSAP1 is linked to central nervous system cancer.